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Background: Hypoxia may contribute to the pathogenesis of various diseases of the vascular wall. Hypoxia-inducible
factors (HIFs) are nuclear transcriptional factors that regulate the transcription of genes that mediate cellular and
tissue homeostatic responses to altered oxygenation. This article reviews the published literature on and discusses the role
of the HIF pathway in diseases involving the vascular wall, including atherosclerosis, arterial aneurysms, pulmonary
hypertension, vascular graft failure, chronic venous diseases, and vascular malformation.
Methods: PubMed was searched with the terms “hypoxia-inducible factor” or “HIF” and “atherosclerosis,” “carotid
stenosis,” “aneurysm,” “pulmonary artery hypertension,” “varicose veins,” “venous thrombosis,” “graft thrombosis,”
and “vascular malformation.”
Results: In atherosclerotic plaque, HIF-1a was localized in macrophages and smooth muscle cells bordering the necrotic
core. Increased HIF-1a may contribute to atherosclerosis through alteration of smooth muscle cell proliferation and
migration, angiogenesis, and lipid metabolism. The expression of HIF-1a is signiﬁcantly elevated in aortic aneurysms
comparedwith nonaneurysmal arteries. In pulmonary hypertension,HIF-1a contributes to the increase of intracellular KD
and Ca2D leading to vasoconstriction of pulmonary smooth muscle cells. Alteration of the HIF pathway may contribute to
vascular graft failure through the formation of intimal hyperplasia. In chronic venous disease, HIF pathway dysregulation
contributes to formation of varicose veins and venous thromboembolism. However, whether the activation of the HIF
pathway is protective or destructive to the venous wall is unclear. Increased activation of the HIF pathway causes aberrant
expression of angiogenic factors contributing to the formation and maintenance of vascular malformations.
Conclusions: Pathologic vascular wall remodelling of many common diseases of the blood vessels has been found to be
associated with altered activity of the HIF pathway. Therefore, understanding the role of the HIF pathway in diseases of
the vascular wall is important to identify novel therapeutic strategies in the management of these pathologies. (J Vasc Surg
2013;58:219-30.)Diseases of vascular wall often cause disruption of
blood circulation leading to end tissue and organ hypoxia.
Pathology within the arterial wall may cause end-tissue and
end-organ ischemia, or even infarction, secondary to inad-
equate oxygen delivery, including in myocardial infarction,
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and hypertension such as in chronic venous insufﬁciency.2
However, hypoxia not only occurs as the result of vascular
diseases but also contributes to the formation of many
pathologies of blood vessel wall in the ﬁrst place, including
in atherosclerosis, aortic aneurysms, pulmonary artery
stenosis, and chronic venous disease. Hypoxia of the
vascular wall is thought to be caused by inadequate blood
vessel wall oxygenation or increased cellular oxygen
demand secondary to various stresses, or both, including
shear stress and elevated hydrostatic pressure.3,4
Hypoxia-inducible factors (HIFs) are heterodimeric
nuclear transcriptional factors consisting of two subunits
that regulate transcription of genes mediating cellular
homeostatic responses to altered oxygenation.5 The HIF-a
subunit (HIF-1a andHIF-2a) is oxygen-regulated, whereas
HIF-b is expressed constitutively in the nucleus. HIF-1a is
expressed in all nucleated cells, and HIF-2a expression is
restricted to speciﬁc cell types, including vascular endothelial
cells, renal interstitial cells, hepatocytes, cardiomyocytes, and
astrocytes.6,7 However, very few HIF-1a and HIF-2a219
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Fig 1. Oxygen-dependent regulation of hypoxia-inducible factor (HIF)-a protein. The blue arrows represent the
sequence of events that occur during normoxia, whereas red lines and arrows indicate those that happen during hypoxia.
The arrows (/) indicate positive effect, and perpendicular lines (a) mean inhibitory effect. CBP, CREB (cyclic
adenosine monophosphate-responsive element-binding) binding protein; E2, ubiquitin-conjugating enzyme; FIH,
factor inhibiting HIF-1; JAB1, Jun activation domain-binding protein-1; OH, hydroxide; PHD, prolyl hydroxylase
domain; Ub, ubiquitin.
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expression of HIF-a in many tissues increases exponentially
as oxygen concentration declines.8 The regulation of
HIF-a by oxygen tension has been extensively studied and
is well understood.
The stability and transcriptional activity of HIF-a are
both negatively regulated by oxygen-dependent hydroxyl-
ation. Under normoxia, HIF-a protein subunits are
hydroxylated on proline residues by HIF-prolyl hydroxy-
lase domain (PHD) enzymes.9-11 For the hydroxylation
reaction, the PHDs require oxygen and a-ketoglutarate
as cosubstrates to catalyze a dioxygenase reaction in which
one oxygen atom is inserted into a-ketoglutarate to form
succinate and carbon dioxide.12 Hydroxylation of a proline
residue of HIF-a is essential for the binding of von Hippel-
Lindau protein, which interacts with elongin C, facilitating
the recruitment of an ubiquitin ligase complex. Ubiquitina-
tion of HIF-a marks it for proteosomal degradation.9,10
Besides prolyl hydroxylation, HIF-1a is also subjected
to hydroxylation of asparagine residue 803 by factor-
inhibiting HIF-1 (FIH-1) during normoxia.13 Asparaginyl
hydroxylation negatively regulates HIF-a transactivation
activity by blocking interaction of the transactivation
domain with the coactivator p300.10 In hypoxia, oxygen-
dependent hydroxylation activity of PHD enzymes and
FIH-1 are both suppressed.14,15 This allows HIF-a to
overcome destruction to dimerize with HIF-b in the
nucleus and binds the hypoxia-responsive element (HRE)
of target genes activating their transcription.5,9,10
Several protein factors are also known to interact with
HIF-a, affecting its stability and activity. For example,C-terminal transactivation domain interacts with transcrip-
tional coactivators, including cyclic adenosine monophos-
phate response element-binding protein and p300, to
activate target gene transcription.16,17 The cJun activation
domain-binding protein-1, or Jab1, stabilizes HIF-a by
blocking hypoxia-dependent degradation and increases its
transcriptional activity.18 The oxygen-dependent regula-
tion of HIF-a protein is summarized in Fig 1. Examples
of HIF-regulated adaptive responses and their correspond-
ing genes are reported in the Table.
Recently, there is increasing evidence supporting the
contribution of the HIF pathway, both protective and
destructive effects, to pathogenesis of diseases affecting
the vascular wall. Therefore, understanding the role of
the HIF pathway, including its paradoxic effects, may
help in identifying a new therapeutic target for these
diseases. This article aims to review the published literature
on and discuss the role of the HIF pathway in diseases
involving the vascular wall, including atherosclerosis, arte-
rial aneurysms, pulmonary hypertension, vascular graft
failure, chronic venous diseases, and vascular malformation.
METHODS
PubMed was searched with the terms “hypoxia-inducible
factor” or “HIF” and “atherosclerosis,” “aneurysm,”
“pulmonary hypertension,” “pulmonary stenosis,” “varicose
vein,” “venous thrombosis,” “venous thromboembolism,”
“graft stenosis,” “graft failure,” “intimal hyperplasia,” or
“vascular malformation.” Only articles written in English
were included. Article titles and abstracts were assessed to
include those that discussed the roles of the HIF pathway in
Table. Examples of hypoxia-inducible factor (HIF)-regulated adaptive responses and their corresponding genes
Adaptive response Genes
Matrix metabolism MMP-1, MMP-3, MMP-2, CATHD, MT1-MMP, TIMP-1, collagen type V (a1), FN1, PAI1, Prolyl-4
hydroxylase-a, UPAR, PHD-2, and PHD-3
Glucose and energy
metabolism
Hexokinase-1 (HK1), HK2, AMF/GPI, ENO1, GLUT-1, GLUT-2, GAPDH, LDHA, PFKBH3, PFKL,
PGK1, PKM, TPI, aldolase-A, aldolase-C, 6-Phosphofructo-2-kinase/fructose-2, 6-biphosphatase-3,
and leptin (LEP)
Amino acid metabolism Transglutaminase 2
Vascular tone a1b-adrenergic receptor, ADM, ET1, HO-1, and NOS2, MMP-2
Angiogenesis VEGF, ENG, LEP, LRP1, TGF-b3,VEGF,ADM, angiopoietin-1 and -2, PAI-1, SDF-1, PlGF, and TGF-a
Erythropoiesis EPO
Apoptosis BNIP3, NIX, and RTP801
Cell survival ADM, EPO, IGF2, IGF-BP1, IGF-BP2, IGF-BP3, NOS2, TGF-a, VEGF, and CYCLIN D1
Motility AMF/GPI, c-MET, LRP-1, and TGF-a
Cell proliferation Cyclin G2, IGF2, IGF-BP1, IGF-BP2, IGF-BP3, WAF1, TGF-a, TGF-b3, p21, and NOS-2
Cytoskeletal structure KRT14, KRT18, KRT19, VIM
pH regulation Carbonic anhydrase 9 and 12
Transcriptional regulation DEC1, DEC2, ETS-1, NUR77, embryonic transcription factors, Oct-4 (Pou5f1, Oct-3/4), and c-Myc
Iron metabolism Ceruloplasmin, transferrin (Tf), and transferrin receptor (Tfr)
Nucleotide metabolism Adenylate kinase 3, and Ecto-5’-nucleotidase
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articles were scrutinized for further relevant articles.
RESULTS
We identiﬁed 313 articles. Of these, 293 were in
English. After reviewing the titles and abstracts of these arti-
cles, 183 articles were included in the review. Of these,
62 articles were for “atherosclerosis,” 7 “aneurysm,”
87 “pulmonary hypertension” or “pulmonary stenosis,” 11
“graft stenosis” or “graft failure” or “intimal hyperplasia,”
9 “varicose veins,” 4 “venous thrombosis” or “venous throm-
boembolism,” and 12 “vascular malformation.”
Atherosclerosis. Hypoxia has been demonstrated to
be present in atherosclerotic plaques, including using
HIF-1a, hypoxia metabolites, and in quantiﬁcations of
various hypoxia markers.4,19 In one study comparing
carotid artery specimens from 50 individuals who under-
went carotid endarterectomy and ﬁve age-matched
controls, HIF-1a expression was signiﬁcantly increased in
the former.19 In another study, pimonidazole, which was
irreversibly metabolized only in hypoxic cells to form
hypoxia-speciﬁc protein adducts, was administered to seven
symptomatic patients before carotid endarterectomy.
Hypoxia was demonstrated using immunohistochemistry
against adducts of pimonidazole in advanced atheroscle-
rotic plaques of symptomatic patients.20 Previous studies
had also directly measured oxygen tension in atheroscle-
rotic aorta and femoral arteries of animalmodelswith oxygen
microelectrodes. Oxygen tension of 0 to 15 mm Hg was
recorded in middle regions of atherosclerotic arteries
compared with 50 mm Hg in normal arteries and in the
adventitia and lumen of atherosclerotic plaques.21,22
Atherosclerotic plaque hypoxia is thought to be contrib-
uted by intimal thickening and calciﬁcation that restrict
oxygen diffusion into the arterial wall. High oxygen demand
has also been measured in metabolically active inﬂammatory
cells, including macrophages, in atherosclerotic plaques.4 Inatherogenesis, hypoxia is known to contribute to increased
angiogenesis,4 release of proinﬂammatory mediators,23,24
activation of matrix metalloproteases (MMPs),25 formation
of reactive oxygen species,26 and dyslipidemia, including
oxidation and loading of low-density lipoprotein
(LDL).27-31 These processes are known to contribute to
the initiation, progression, and ﬁnally, destabilization of
atherosclerotic plaques.4
In human atherosclerotic plaques, HIF-1a protein
was found to localize in perivascular tissues, inﬂammatory
macrophages, and smooth muscle cells (SMCs) bordering
the necrotic core.4,19 Such ﬁndings support the association
of HIF-1a with angiogenesis and inﬂammation in athero-
sclerosis.20,32-35 Various genes regulated by HIF have
been postulated to contribute to atherogenesis (Fig 2).4
Increased HIF-1a secondary to hypoxia may affect vascular
SMC (VSMC) proliferation and migration. The expression
of macrophage migration inhibitory factor (MIF), a proin-
ﬂammatory factor that regulates proliferation and migra-
tion of VSMC, has been shown to be affected by HIF-1a
in human VSMCs exposed to hypoxia.36 Studies also
showed HIF-1a and its angiogenic target genes were asso-
ciated with angiogenesis in atherosclerosis, leading to pla-
que progression, hemorrhage, and ulceration.33,35 One
study assessing 29 human carotid plaques from endarterec-
tomy found HIF-1a, vascular endothelial growth factor
(VEGF), and E26 transformation-speciﬁc-1 (Ets-1) colo-
calized in the deep layer of plaque, where angiogenesis
was remarkably developed.35 Ets-1 is an oncogenic tran-
scriptional factor that has important roles in embryogen-
esis, wound healing, and tumor progression by activating
the transcription of genes associated with angiogenesis,
proliferation, and metastasis.37 The expression of VEGF
and Ets-1 was signiﬁcantly increased in plaques with
hemorrhages, ulceration, and severe stenosis, features asso-
ciated with symptomatic atherosclerosis.35 However, the
association of HIF-1a and symptomatic plaques remains
HIF Pathway 
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Fig 2. Summary of the effects of the hypoxia-inducible factor (HIF) pathway activation in atherosclerosis and arterial
aneurysms. Bid, BH3-interacting domain death agonist; Ets-1, E26 transformation-speciﬁc-1; GLUT-1, glucose trans-
porter 1; HO1, heme oxygenase 1; MCP-1, monocyte chemotactic protein-1; MMP, matrix metalloprotease; NF-kB,
nuclear factor-kB; NOS2, nitric oxide synthase 2; PAI-1, plasminogen activator inhibitor 1; PPAR-a, peroxisome
proliferator-activated receptor a; VCAM-1, vascular adhesion molecule 1; VEGF, vascular endothelial growth factor.
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did not vary between symptomatic and asymptomatic
patients.32
Increased HIF-1a activity secondary to hypoxia may
alter lipid metabolism in macrophages and VSMCs,
contributing to foam cell and atherosclerotic plaque forma-
tion. An in vitro study found RNA interference for HIF-1a
with small-interfering RNA inhibited foam cell formation
by the human monoblastic cell line treated with oxidized
LDL.38 HIF-1a has been shown to contribute to triglyc-
eride accumulation and increase sterol content secondary
to the induction of sterol synthesis and suppression of
cholesterol efﬂux in hypoxic macrophages.39-41 HIF-1a
and HIF-2a also regulate the synthesis and expression of
proteoglycans in macrophages, which can modulate the
retention of lipoproteins that may be involved in athero-
genesis.42 In a study using human monocyte-derived
macrophages, hypoxia augmented the interaction between
glycosaminoglycans and LDL.43 In hypoxic VSMCs,
increased HIF-1a activated the transcription of LDL
receptor-related protein (LRP1). Hypoxia effects on
LRP1 protein expression were functionally translated into
an increased cholesteryl ester accumulation from aggre-
gated LDL uptake. Furthermore immunohistochemistry
demonstrated colocalization of LRP1 and HIF-1a in
vascular cells of advanced atherosclerotic plaques in
humans.44
Arterial aneurysms. Arterial aneurysms have been
shown to be hypoxic in several studies.45-47 Intraluminal
thrombus, a common feature of aneurysms, may contributeto arterial wall hypoxia.46,48 Hypoxia may alter VSMC
function, leading to weakening of the arterial wall.49,50
Hypoxia may also stimulate inﬂammatory processes and
cause imbalances of MMPs and tissue inhibitors of MMPs
(TIMPs), leading to an increase in elastin and collagen
destruction. Not all MMPs or TIMPs are upregulated by
hypoxia, and their regulation may vary with tissues and
disease processes. For example, MMP-2 is thought to play
a crucial role in the initiation of abdominal aortic aneu-
rysms (AAAs), whereas MMP-9 may be important in early
and late aneurysm formation.51
The expression of HIF-1a is signiﬁcantly elevated in
aneurysmal arteries compared with nonaneurysmal arteries.
Hu et al52 found that the expression of HIF-1a messenger
(m)RNA and protein was signiﬁcantly increased in AAAs
compared with normal abdominal aortic specimens (22
AAAs and ﬁve controls). Using immunohistochemistry,
the authors found that HIF-1a positivity was mostly in
VSMCs and adventitia of AAAs. The expression of VEGF
and caspase-3 was also higher in AAAs than in normal
aortas, and both had a signiﬁcantly positive relationship
with HIF-1a expression.52
Erdozain et al53 used immunohistochemistry to
analyze 36 AAAs and 12 normal aortic specimens (aortic
cuff of renal transplant donors) for HIF-1a, MMP-2, and
Ets-1 transcription factor. In each patient, aortic sections
were obtained from the proximal, body, and distal region.
HIF-1a staining was intensely localized to the nuclei of
cells within the tunica media and inﬂammatory inﬁltrate
of all AAAs analyzed compared with the less intense
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predominantly localized to the nucleus in all AAA tissues
examined compared with cytoplasm in normal aortas.
This was thought to be due to nuclear translocation that
has occurred secondary to hypoxia in AAAs. HIF-1a
expression was also most abundant in the body of the
AAAs, suggesting that HIF-1a may be implicated in AAA
progression. The distribution of MMP-2 and Ets-1 expres-
sion in the AAAs was also similar to that of HIF-1a. In the
same study, the authors also exposed human aortic SMCs
(HASMCs), cultured from normal aortas, to experimental
hypoxia. The expression of HIF-1a, Ets-1, VEGF, and
MMP-2 was signiﬁcantly upregulated in HASMCs exposed
to hypoxia compared with those in normoxia. On the basis
of the sequence of ﬁndings, the authors explained that
exposure of HASMCs to hypoxia caused stabilization of
HIF-1a protein and subsequent nuclear translocation and
binding of HIF-1a to the HRE of VEGF and Ets-1, thus
resulting in the transcription of these target genes. The
MMP-2 was thought to be upregulated by Ets-1, hence,
a delayed rise of MMP-2.53
In one mouse model study, the abdominal aorta was
transiently perfused with elastase (n ¼ 61) or heat-
inactivated elastase as the control (n ¼ 68). All abdominal
aortas that were perfused with elastase gradually developed
into an aneurysm compared with none of the controls.
Between the elastase and control groups, there were 384
genes with signiﬁcant differences in expression for at least
one interval after aortic perfusion, including 234 with
differential upregulations and 163 with differential downre-
gulations. HIF-1a gene expression was upregulated by
more than 20-fold, suggesting that it may play an impor-
tant role in AAA development.54
Increased expression of HIF-1a has also been reported
in inﬂammatory aortic aneurysms compared with nonin-
ﬂammatory aneurysms. One study found HIF-1a immuno-
staining was positive in spindle ﬁbroblastic or histiocytic
cells in periaortic tissues of 3 of 11 inﬂammatory aortic
aneurysms compared with none of the 12 matched nonin-
ﬂammatory aortic aneurysm controls that were matched for
age, sex, and date of operation.55 Because the sample size
was small, larger studies are required to further investigate
the role of the HIF pathway in inﬂammatory aortic aneu-
rysms. Besides inﬂammation, increased expression of
HIF-1a has also been implicated in ruptured AAAs. In
one study, paired samples of aneurysm rupture edge and
anterior aneurysm wall (2 cm distal to left renal vein)
obtained during emergency open repair for ruptured AAAs
(n ¼ 12) were analyzed with quantitative polymerase chain
reaction and immunohistochemistry. The mRNA and
protein expression of HIF-1a was signiﬁcantly increased in
the aneurysm rupture edge comparedwith the anterior sac.45
Besides aortic aneurysms, HIF-1a has also been impli-
cated in saccular intracranial aneurysms. One study used
oligonucleotide microarray to compare the whole-
genome expression proﬁle of 11 ruptured saccular intracra-
nial aneurysm wall samples with that of eight nonruptured
samples. After the screening of the expression of 17,788distinct genes, 686 genes were signiﬁcantly upregulated
and 740 were downregulated in the ruptured saccular
intracranial aneurysm walls compared with the nonrup-
tured ones. Signalling pathway and transcription factor
analyses suggested that Toll-like receptor signalling and
regulation by nuclear factor (NF)-kB, HIF-1a, and Ets
transcription factors have key roles in the processes active
in the ruptured saccular intracranial aneurysm walls.56
The role of the HIF pathway in the pathogenesis of
arterial aneurysms remains incompletely understood.
MMPs and TIMPs imbalances, as well as VSMC pheno-
type alteration caused by the HIF pathway, are likely
important because they are crucial in maintaining arterial
wall strength. Other HIF-regulated processes may also
contribute but have not yet been investigated. For
example, abnormal lipid metabolism has been shown in
patients with AAAs,57 although the role of the HIF
pathway in such lipid metabolism has never been studied.
Fig 2 summarizes the effects of the HIF pathway in
atherosclerosis and arterial aneurysms. It is unclear what
factors determine whether the activation of the HIF
pathway will lead to atherosclerosis or aneurysms, although
this is likely multifactorial.
Pulmonary hypertension. Prolonged exposure to
alveolar hypoxia, secondary to chronic lung disease or high
altitude, is an important cause of hypoxic pulmonary hyper-
tension.58 Acute hypoxia induces vasoconstriction causing
a reversible increase in pulmonary vascular resistance.
Hypoxia also stimulates vascular remodelling processes in
hypoxic pulmonary hypertension, which include increased
proliferation, migration, and impaired apoptosis of pulmo-
nary artery SMCs (PASMCs), accumulation of extracellular
matrix, and myoﬁbroblast formation.58-61
Various mediators regulated by HIF have been demon-
strated to be activated, including ET-1, angiotensin-1
receptor, VEGF, platelet-derived growth factor-b, endo-
thelial and inducible nitric oxide synthase, and erythropoi-
etin.62 Heterozygous HIF-1a (HIF-1aþ/e) and HIF-2a
(HIF-2aþ/e) knock-out mice demonstrated delayed mani-
festation of, or protection against, hypoxia-induced pulmo-
nary hypertension through reduction of hypoxia-induced
PASMC depolarization and hypertrophy.63-65
Several HIF-dependent responses of PASMCs to
hypoxia have been reported to contribute to the patho-
physiology of hypoxic pulmonary hypertension. For
example, HIF-1a has been reported to inhibit the expres-
sion of the voltage-gated potassium (Kþ) channels through
the induction of ET-1 and activate transient receptor
potential cation channel 1 and channel 6 store-operated
calcium (Ca2þ) channels in PASMCs.64,66,67 These mech-
anisms contribute to the increase of intracellular Kþ and
Ca2þ, which trigger depolarization of PASMCs and
pulmonary vasoconstriction. HIF-1a has also been
observed to induce the expression of the sodium hydrogen
exchanger 1 and alter the intracellular pH homeostasis
leading to PASMC proliferation.68 HIF-1a also regulates
angiotensin-converting enzyme, which is known to
enhance the proliferation and migration of PASMCs.
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PASMC proliferation through the induction of the fork-
head box M1, a transcription factor that regulates cell
cycle.69 HIF-2a also plays a role in the activation of argi-
nase II in human lung microvascular endothelial cells.70
Arginase II modulates the level of nitric oxide production
in endothelial cells, and its expression has been reported
to be elevated in the lungs of patients with pulmonary
hypertension.71
Normoxia activation of the HIF pathway may also
contribute to pulmonary hypertension. Immunohisto-
chemistry of lung tissues from patients with nonhypoxic
pulmonary hypertension, including primary pulmonary
hypertension, pulmonary hypertension secondary to left-
to-right heart shunt, and pulmonary hypertension associ-
ated with liver cirrhosis and CREST (calcinosis, Raynaud0s
syndrome, esophageal dysmotility, sclerodactyly, telangiec-
tasia) syndrome, demonstrated increased expression of
HIF-1a and VEGF receptor (VEGFR)-2.72 Another study
found mitochondrial superoxide dismutase 2 (SOD2) deﬁ-
ciency in pulmonary arteries and plexiform lesions of
pulmonary hypertension.73-75 SOD2 regulates the produc-
tion of hydrogen peroxide, which in turn inhibits the
activity of HIF-1a.76,77 Such a decrease in SOD2 is
thought to be caused by epigenetic mechanisms.77
Graft failure. Evidence supports that vascular graft
(both vein and prosthesis) failure results primarily from
stenosis caused by intimal hyperplasia that may subse-
quently cause occlusion and thrombosis.78 Intimal hyper-
plasia is a proliferative process that involves migration and
phenotypic switch of SMCs and ﬁbroblasts, activation of
inﬂammatory cells, matrix deposition, imbalances of MMPs
and TIMPs, and angiogenesis.79-84 The mechanism of
intimal hyperplasia initiation and development remains
incompletely understood and is likely multifactorial.82,85,86
For example, endothelial injury and ischemia secondary to
tissue handling during the harvesting process and reperfu-
sion during implantation are likely to contribute to intimal
hyperplasia formation in vein graft.82 Several hemodynamic
factors, including hypoxia, low and high wall shear stress,
and mechanical strain, have also been postulated to
contribute to intimal hyperplasia formation.85,87-96
There is evidence to support that hypoxia contributes
to intimal hyperplasia formation. Prosthetic grafts used as
arterial conduits in studies with animal models showed
increased hypoxia within the vessel wall in regions of
intimal hyperplasia.97,98 One animal model study also re-
ported that reducing hypoxia might hinder venous intimal
hyperplasia formation, possibly by reducing the phenotypic
switch of ﬁbroblasts that migrated from adventitia to neo-
intima to form myoﬁbroblasts.99 The same study also
demonstrated an association of HIF-1a expression with
the degree of intimal hyperplasia in the grafts.
Evidence from studies of hemodialysis vascular access
suggests that graft failure may be associated with increased
activation of the HIF pathway. Misra et al87 investigated
hypoxia-associated factors that might contribute to the
inferiority in the patency of prosthetic graft as comparedwith vein conduits in hemodialysis vascular access. The
authors compared the expression of HIF-1a, macrophage
MIF, and several MMPs and TIMPs between whole-
vessel tissue samples from the vein distal to the vein-to-
polytetraﬂuoroethylene (PTFE) graft anastomosis and the
proximal outﬂow vein of the arteriovenous ﬁstula (AVF)
of patients who required surgical revision of thrombosed
and stenosed conduits, as well as native nondilated and
nonstenotic vein of patients undergoing hemodialysis
vascular access formation as controls.87 Specimens from
patients with PTFE grafts expressed signiﬁcantly more
HIF-1a, MIF, TIMP-1, pro-MMP-2, and pro-MMP-9
compared with control veins. Only pro-MMP-9 was signif-
icantly upregulated in AVFs compared with control
samples. The expression of MIF and TIMP-1 was signiﬁ-
cantly increased in PTFE graft specimens compared with
AVFs. The expression of HIF-1a in AVFs seemed to be
higher than in controls but was lower than in thrombosed
PTFE grafts, although the differences were not statistically
signiﬁcant in the study. The authors concluded that there
were major differences in the expression HIF-1a and
proteins regulated by HIF-1a in specimens removed
from patients with PTFE grafts and AVFs. The authors
also developed porcine and mouse models of vascular
access failure in the background of chronic renal failure
and found that HIF-1a and similar HIF-1a-associated
protein expressions were increased in failed conduits
compared with controls.85,100
Interestingly, increased activation of the HIF pathway
may also protect against intimal hyperplasia formation.
One study in a rat model found that inferior vena cava
(IVC) conduits that were immediately implanted as inter-
positional grafts into the abdominal aorta after harvest
demonstrated signiﬁcantly less intimal hyperplasia after 3
and 6 weeks than those treated with cold lactated Ringer
solution for 2 hours. However, treatment in lactated
Ringer solution saturated with carbon monoxide signiﬁ-
cantly inhibited intimal hyperplasia development compared
with those untreated with carbon monoxide. The effects of
carbon monoxide in inhibiting intimal hyperplasia forma-
tion seemed to be associated with upregulation of HIF-
1a and VEGF expression at 3 to 6 hours after grafting.
Such protective effects including the induction of VEGF
were found to be reversed by treatment with YC-1,
an HIF-1a inhibitor, supporting that these effects were
mediated through the activation of the HIF pathway.82
Such paradoxic effects of the HIF pathway activation on
intimal hyperplasia in the bypass graft suggest that tight
regulation of the pathway is important in determining its
effects. One possibility is that transient activation of the
HIF pathway may protect tissues from hypoxia, whereas
chronic activation may be destructive.
Varicose veins. Vein wall hypoxia secondary to blood
stasis has been postulated to contribute to varicose vein wall
changes.3,101 Although ﬁndings from studies comparing the
oxygen content in blood from varicose and nonvaricose veins
have been inconclusive, direct measurement of vein wall
oxygen tension by Taccoen et al102 demonstrated that the
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varicose compared with nonvaricose veins (7.9 vs 13.4 mm
Hg; P < .05), suggesting that varicosities may be associated
with hypoxia.3,102
The internal spermatic veins of patients with varico-
celes, a condition similar to varicose veins, were reported to
express signiﬁcantly more HIF-1a than those of patients
without the disease.103,104 Hossein-Ghaderian et al105 were
ﬁrst to describe increased expression of HIF-1a in varicose
compared with nonvaricose veins. We recently found that
the mRNA and protein expression of both HIF-1a and
HIF-2a and target genes (glucose transporter-1, carbonic
anhydrase-9, VEGF, and B-cell lymphoma 2/adenovirus
E1B19-kDaprotein-interactingprotein3)wereupregulated
in varicose comparedwithnonvaricose veins.We also showed
that varicose and nonvaricose veinswere able to activate both
HIF-1a and HIF-2a protein and target genes expression
when subjected to in vitro hypoxic and conditionsmimicking
hypoxia.106
Besides hypoxia, venous tissue is also able to activate
the HIF pathway through mechanical stretch. One study
subjected segments of rat IVC suspended in a tissue bath
to different vein wall tension and duration with or without
HIF inhibitors and measured IVC contraction.107 Pro-
longed increases in vein wall tension were associated
with overexpression of HIF-1a and HIF-2a, increased
MMP-2 and MMP-9 expression, and reduced venous
contraction in rat IVC.
Venous thromboembolism. Severe hypoxia from pro-
longed stasis has been reported at the level of the deepest
recesses of the venous valvular sinuses of dogs without calf
muscle,108 which corresponded to the anatomic locations
of thrombus initiation.109 Hypoxia associated with blood
stasis is thought to activate several hypoxia-adaptive
responses, including the HIF and early growth response-1
pathway. These pathways are known to promote endothe-
lial permeability and activation, coagulopathy, and recruit-
ment of inﬂammatory cells. HIF-1a can contribute to the
initiation or development of venous thrombosis through its
target genes, including VEGF, which affects endothelial cell
permeability and PAI-1, which inhibits thrombus ﬁbrino-
lysis. Upregulation of HIF-1a in endothelial cells and
myeloid-derived phagocytic cells, such as monocytes and
macrophages, can also contribute to venous thrombosis by
stimulating proinﬂammatory processes through mediators
including tumor necrosis factor-a, interleukin-1, and NO.
Furthermore, the interdependency relationship between the
HIF pathway and NF-kB, an innate immune response
regulator, is also thought to be important.110-112
Besides venous thrombogenesis, activation of HIF-1a
has been reported to contribute to thrombus resolu-
tion113,114 through the promotion of angiogenesis and
recruitment of endothelial progenitor cells. Venous
thrombus resolution is important clinically because deep
veins that recanalize more quickly after thrombosis have
a reduced incidence of post-thrombotic syndrome.115-117
Evans et al118 used a mouse model to demonstrate the
importance of HIF-1a in the thrombus and vein wall inpromoting venous thrombus resolution. The authors
used a combination of blood ﬂow restriction and endothe-
lial disturbance to induce experimental thrombi in mouse
IVC. The oxygen tension measured within the thrombus
had an inverse relationship with HIF-1a level and time of
thrombus resolution, whereas HIF-1a expression was posi-
tively associated with the amount of VEGF. Meanwhile,
within the vein wall of the thrombus IVC, the level of
HIF-1a was relatively constant throughout the thrombus
resolution, whereas VEGF and placental growth factor
expression was increased, suggesting the angiogenic drive
in the vein wall surrounding the naturally resolving
thrombus was independent of HIF-1a.118
The authors further investigated the effect of activation
of the HIF pathway on venous thrombus resolution by
treating some of the mice with L-mimosine, a PHD inhib-
itor, which therefore increased the expression of HIF-1a.
Mice treated with L-mimosine increased expression of
HIF-1a, VEGF, VEGFR1, and 13 other HIF-1a-mediated
angiogenic factors, including angiopoietin, endoglin,
ET-1, and leptin, in the thrombus compared with controls
treated only with vehicles. Meanwhile, the expression of
HIF-1a, VEGF, and placental growth factor was signiﬁ-
cantly increased in the vein wall of the IVC thrombus in
mice treated with L-mimosine compared with controls.
Mice treated with L-mimosine also showed signiﬁcantly
reduced thrombus weight and volume, as well as increased
vein recanalization, thrombus neovascularization, and asso-
ciated inﬂammatory cells compared with controls. The
authors concluded that upregulation of HIF-1a levels in
the environs of the thrombus promotes an angiogenic
milieu that drives resolution.119
Vascular malformations. Aberrant expression of
angiogenic factors secondary to hypoxia has been impli-
cated in the formation and maintenance of vascular malfor-
mations.120 That HIF is implicated in the pathogenesis of
various vascular malformations is therefore not surprising.
Cutaneous and leptomeningeal vascular malformations
are hallmarks of Sturge-Weber syndrome (SWS), a rare
congenital, noninherited neurocutaneous disorder affecting
the cephalic venous vasculature.121 Increased expression of
nuclear HIF-1a andHIF-2a protein along with genes regu-
lated by HIF, including VEGF, its cognate receptors
VEGFR-1, VEGFR-2, and neuropilin-1, and TIE-2, has
been demonstrated in SWS blood vessels.121 Besides SWS,
HIF-1a is highly expressed in cerebral arteriovenous mal-
formations, and its expression was associated with VEGF
and VEGFR, supporting its role in promoting angiogen-
esis.122,123 Increased expression of HIF-1a and VEGF has
also been shown in dural AVFs.124 Although the exact path-
ogenesis of dural AVFs is unclear, sinus occlusion or venous
hypertension may play an important role.124
Using a mouse brain venous hypertension model, Gao
et al125 demonstrated that venous hypertension caused
a proangiogenic stage in the brain by upregulating
HIF-1a and its downstream targets, VEGF and stromal
cell-derived factor-1a and increasing leukocyte inﬁltration,
MMP-9 activity, and capillary density in the parasagittal
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Fig 3. Pathologic processes caused by increased activation of the hypoxia-inducible factor (HIF) pathway that lead to
vascular wall remodelling in diseases of arteries and veins.
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of vascular malformations. In a recent study, the expression
of HIF-1a was increased in arteriovenous malformation
specimens from patients with a higher Schobinger clinical
stage.126 Other vascular malformations in which increased
expression of HIF-1a or HIF-2a, or both, has been
observed include gastrointestinal vascular malformation,127
cutaneous capillary hemangioma,128 and cerebral cav-
ernous malformations.129
Summary and future perspective. The HIF pathway
contributes to the regulation of physiologic and pathologic
vascular wall remodelling. Pathologic vascular wall remod-
elling of many common diseases of the blood vessels has
been found to be associated with an altered HIF pathway.
Important vascular remodelling processes in common
diseases of the vascular wall that are associated with
increased activation of the HIF pathway are summarized
in Fig 3. The upregulation of the HIF pathway activity in
pathologic vascular wall remodelling is likely to be caused
by hypoxia secondary to inadequate oxygen supply or
increased oxygen demand, or both, as a result of various
cellular stresses. However, it is not clear at this stage if the
increased activation of the HIF pathway in diseases of the
vascular wall is overall protective or disruptive. The
expression and activation of HIF may protect the cells in
the vascular wall from the stresses including hypoxia, shear
stress, and mechanical stretch. On the other hand, over-
expression of HIF may lead to various changes in the cells,
including increased proliferation of SMC, degradation of
extracellular matrix proteins, and alteration of vascular tone
causing pathologic vascular wall remodelling. It is likely
that in the initial event of these diseases of the vascular wall,
the HIF pathway is activated to protect vascular cells from
hemodynamic stresses. Chronically recurring stresses lead
to repeated activation of the HIF pathway in the vascular
wall, causing excessive changes that ultimately contribute
to pathologic remodelling of the blood vessels. However,
this hypothesis remains a speculation at present and
therefore warrants further investigation.Targeting the HIF pathway with pharmacologic agents
or gene therapy is an attractive and potential therapeutic
strategy in the management of diseases of the vascular
wall. Drugs that inhibit HIF-a expression or activity are
being developed and tested for the treatment of diseases
associated with increased expression of HIF-a, including
cancers.130,131 Examples of HIF inhibitors include
EZN-2968,132 sorafenib,131 and echinomycin.133 On the
other hand, drugs that increase the activity of HIF-a are
being developed for diseases such as ischemic heart
diseases, stroke, peripheral arterial diseases, and chronic
anemia.134-136 The most important group of drugs that
increase the expression and activity of HIF-a are the
HIF-PHD inhibitors.134,135 This group of drugs inhibits
HIF-PHD, thereby “stabilizing” HIF by preventing pro-
teosomal degradation.134,135 Examples of HIF-PHD
inhibitors include dimethyloxalylglycine, desferrioxamine,
and 3,4-dihydroxybenzoate. FG-2216 and FG-4592 are
two orally active HIF-PHD inhibitors being tested in clin-
ical trials for the treatment of chronic anemia in patients
with long-term kidney disease.8,137
CONCLUSIONS
Pathologic vascular wall remodelling of many common
diseases of the blood vessels has been found to be associ-
ated with altered activity of the HIF pathway. Clearly,
there is a need to further investigate the effect of the
above-described inhibitors and activators of the HIF
pathway in vascular diseases. This will allow us to under-
stand more precisely the involvement and the role of this
very important master regulator of oxygen homeostasis in
diseases of the vascular wall and identify new and more
effective treatment.
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